Skip to main content
. 2019 Mar 7;9:3909. doi: 10.1038/s41598-019-40602-w

Figure 4.

Figure 4

Enhanced plaque stability in ApoE−/− regression mice treated with rivaroxaban. (A)Top row represents images of atherosclerotic plaque in the aortic arch stained with sirius red, used to quantify total collagen of atherosclerotic plaque under polarized light after 14 and 20 weeks. (B) Quantitative analysis of total collagen in atherosclerotic plaque after 14 weeks: 27.62% (23.79–30.76) and 20 weeks: 22.65% (20.73–25.65) vs 37.03% (31.24–43.21). (C)Atherosclerotic plaque in the aortic arch, stained with sirius red, used to quantify the mean fibrotic cap thickness of atherosclerotic plaque after 14 and 20 weeks. (D) Quantitative analysis of mean fibrotic cap thickness after 14 weeks: 29.50 μm (26.00–40.50) and 20 weeks: 20.00 μm (15.50–25.75) vs 35.00 μm (28.00–38.00). (E) Top row represents images of atherosclerotic plaque in the aortic arch stained against αSMA, used to quantify the expression of VSMC in atherosclerotic plaques. (F) Quantitative analysis of αSMA expression in atherosclerotic plaques after 14 weeks: 12.02% (10.83–15.55) and 20 weeks: 9.98% (8.98–11.91) vs 16.11% (13.95–19.04). All data were median (IQR), *p < 0.05 vs 14 weeks, n = 10 for each group.